Vanguard Global Advisers
CMPX icon

Vanguard Global Advisers’s Compass Therapeutics CMPX Stock Holding History

Vanguard Global Advisers’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$134K Sell
61,158
-33,760
-36% -$99.7K ﹤0.01% 2665
2026
Q1 		$502K Buy
+94,918
New +$548K ﹤0.01% 2042

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.49% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Global Advisers's CMPX Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Compass Therapeutics (CMPX) stake by 36% in Q2 2026, selling an estimated $99.7K and leaving 61,158 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #2665.

Vanguard Global Advisers first reported a position in CMPX in Q1 2026 and has held it in 2 quarters since. The position peaked at $502K in Q1 2026. 213 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Vanguard Global Advisers held 61,158 shares of Compass Therapeutics worth $134K as of Q2 2026.
  • Vanguard Global Advisers sold 33,760 Compass Therapeutics shares in Q2 2026, an estimated $99.7K.
  • Compass Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2665 holding.
  • Vanguard Global Advisers first reported a position in Compass Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Compass Therapeutics position peaked at $502K in Q1 2026.
  • 213 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.